Endonovo Therapeutics Inc (ENDV)

[Dutchdaan]

"Endonovo's Technology Make's us A Monopoly"

Drug companies have spent billions on small molecules and biologics to address a multitude of inflammatory conditions with little to no avail.

To name a few:

-GlaxoSmithKline(NYSE$41.37)
-Google parent Alphabet’s($843.25)
-Delmar Pharmaceuticals(US$ 4,29),
-Celator Pharmaceuticals (+1,610% in 2016 $30.24 Nasdaq)
-ProNAi Therapeutics($1.49).

They all have taken a different route then Endonovo Therapeutics Inc has.

Endonovo’s technology is much simpler to use and targets the cells and organs directly, rather than through the nerves. Its technology is also fundamentally different than implantable stimulators because the electrical fields generated by its technology are much lower in power than those used to stimulate nerves. The weak electrical fields used by Endonovo’s technology are used to enhance the natural regenerative properties of cells.

All of ENDV`s competition are listed on the Nasdaq, we have a monopoly at this point because we took a different route. Pre clinical results look extremely promising.

*Big Pharma has begun to invest heavily in Bioelectronic Medicine*

Big Pharma is transforming right in front of our eyes and in the not too distant future, you may not recognize it. In fact, the next blockbuster treatment may not be a drug at all, but rather an electroceutical.

For over a century, medicine has centered on chemistry and biology to treat disease. However, that is rapidly changing toward the use devices that are capable of speaking the body's electric language to treat human ailments and diseases. This new age of medicine is commonly referred to as "Bioelectronic Medicine," and it seeks to use electroceuticals rather than drugs to treat disease.

Big Pharma has recognizes the potential of electroceuticals and has begun to invest heavily in this new field of medicine.

For example, GlaxoSmithKline has teamed up with Google's parent company to form a $715 million joint venture called Galvani Bioelectronics to develop and commercialize electroceutical products.

Merck & Co. invested in a non-invasive vagus nerve stimulator (VNS) to treat migraine headaches. Novartis is developing a smart contact-lens that will allow diabetics to monitor themselves continuously by measuring the glucose level in their tears; and Johnson & Johnson (J&J) has invested in an implantable electroceutical for treating heart failure.

One company that investors interested in biotech should take note of is Endonovo Therapeutics, Inc. (ENDV). It recently announced that it had signed a term sheet to raise $5 million from a strategic healthcare investor, as part of a larger $15 million round of financing to uplist the company onto a national stock exchange and to develop a pipeline targeting vascular diseases and ischemia/reperfusion injuries using its non-invasive electroceutical. ENDV's non-invasive technology, which it calls "Immunotronics", uses time variant magnetic pulses to control the inflammatory response and promote the formation of new blood vessels.

Some of the conditions that ENDV is targeting include ischemic stroke, myocardial infarction, peripheral artery disease, as well as ischemia/reperfusion injury in the liver and kidneys.

The life threatening and debilitating conditions that Endonovo is seeking to treat are among the largest with clinical unmet needs. For example, between 2012 and 2030, total direct medical stroke-related costs are projected to triple, from $71.6 billion to $184.1 billion, with the majority of the projected increase in costs arising from patients 65 to 79 years of age. Furthermore, over 6.8 million Americans are estimated to have peripheral artery disease, according to the American Heart Association.

in billions


So should investors be bullish on electroceuticals as well?

The bottom line is that as strategic investors, you will be looking at the magnitude of the opportunity at hand and assessing the level of risk involved. In biotech, investors always tend to have huge appetites for high risks due to the potential payout that could come once a product reaches the market.

With its non-invasive approach, large potential opportunity in vascular diseases/ischemia and a valuation that is hovering just above its 52 week low, ENDV is a company that presents a potentially favorable risk/reward profile for biotech investors concentrated on growth.

***********************************************************************

Amazing DD! Endonovo Mentioned in Report on Why Bioelectronics are the Future of Medicine.

Quantum mechanics have redefined what we know about the Newtonian material universe – scientists are now beginning to realize everything in the universe is made of energy. In the field of medicine, doctors began realizing nerves use electrical pulses to control the functions of organs. Every cell produces electromagnetic fields at unique frequencies and controlling these electrical pulses and electromagnetic fields could be a potentially lucrative avenue for biotech companies and investors looking to control everything from bone growth to inflammation.

In this article we take a closer look at the bioelectronics industry and why Endonovo Therapeutics Inc. (OTC: ENDV) is well positioned to capitalize on these revelations.

What is Bioelectronics?

Bioelectronics is broadly focused on the convergence of biology and electronics. The most popular example of bioelectronics is the pacemaker and medical imaging technologies but the modern industry has shifted towards a substantially different focus. For example, GlaxoSmithKline plc (NYSE: GSK) teamed up with Alphabet Inc.’s (NASDAQ: GOOGL) Verily Life Science LLC to develop implants to control inflammatory, metabolic, and endocrine disorders.

“Many of the processes of the human body are controlled by electrical signals firing between the nervous system and the body’s organs, which may become distorted in many chronic diseases,” said GSK’s Moncef Slaoui when announcing the partnership. “Bioelectronic medicine’s vision is to employ the latest advances in biology and technology to interpret this electrical conversation and to correct the irregular patterns found in disease states.”

There are two ways that companies have approached the idea of modifying these electrical conversations in the body – non-invasive and invasive.

The first approach uses pulsed electrical magnetic fields – or PEMF – applied to the skin in order to elicit a cellular response depending on their amplitude, frequency, and waveform. Since the late-1970s, the FDA has approved these devices to treat everything from non-union fractures to Major Depressive Disorder. The most obvious advantage of this approach is not involving surgery but its effectiveness tends to vary widely by technology.

The second approach uses small electronic implants often applied directly to the vagus nerve to control outcomes. This approach requires careful surgery to accomplish while entailing greater risk. The first of these devices were approved in 1997 for the treatment of seizures, but the success of the device was mixed and the industry continues to push for greater efficacy.

Endonovo’s Unique Focus

Endonovo Therapeutics Inc. (OTC: ENDV) has taken the non-invasive approach, but uses a different technique than most PEMF companies. Its focus is on time-vary electromagnetic fields – or TVEMF – that produce intense square waveform magnetic pulses that are just 0.0001 seconds wide in order to achieve deep tissue penetration and elicit a more potent cellular response. While sine waves take a long time to reach peak intensity, square waves do so much faster without having to increase the frequency. This enables Endonovo to bring down the frequency of its TVEMF and avoid potential tissue damage resulting from the heating of tissue.

The company is leveraging its TVEMF approach in two critical areas. Its Immunotronics™ program is designed to promote an anti-inflammatory response and promote tissue repair in patients in danger of and/or experiencing the failure of vital organs due to a severe immune response to infections or injuries. Since these patients often cannot be operated on, the non-invasive nature of the procedure provides a significant potential benefit and eliminates the potential competition from the surgical side of the industry.

Its Cytotronics™ platform uses a similar approach for creating more potent cell therapies and biologics. TVEMFs can be used to expand stem cells in the lab and increase the expression of dozens of genes related to cell growth, tumor suppression, cell adhesion, and extracellular matrix production. By taking a physics approach to biology, the company aims to create bioelectronically-expanded stem cells with enhanced biological and therapeutic properties.

Endonovo's technology already has shown tremendous promise in pre-clinical trials ranging from the reduction of acute inflammation to regenerating bone in animals. The company is now targeting inflammation in vital organs and augmenting the regeneration of organs like the liver in the hope that one day transplants may be a thing of the past. In the process, the company could compete with companies like GSK and Alphabet targeting the surgical implant approach.

Looking Ahead

Bioelectrical medicine is a rapidly advancing field that holds tremendous promise across a number of difficult-to-treat conditions. While some companies are targeting a surgical approach, Endonovo aims to develop highly-effective non-invasive therapies that can be used directly on patients and on cell lines to improve outcomes and develop new therapeutics.

The company recently provided an update on its current research and development stating it expects to conduct a pre-clinical study to evaluate the effectiveness of its Immunotronics technology in accelerating the regeneration of the liver in the first quarter of 2017. It also intends to uplist its common stock onto a national stock exchange in the first half of 2017.